- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03941093
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Study Overview
Status
Conditions
Detailed Description
Participants will be randomized in a 1:1 ratio to one of the two study treatment arms; pamrevlumab with either G/NP or FOLFIRINOX, placebo with G/NP or FOLFIRINOX.
Each participant may receive up to 6 cycles of treatment (each treatment cycle is 28 days). Tumor tissue will be collected during resection to determine surgical outcome and for biomarker analysis. Tumor response will be evaluated by changes in CT scan, FDG-PET, CA 19-9, and NCCN® guidelines.
All participants randomized will have a safety follow-up visit approximately 28 days after the last dose of study treatment and a final safety follow-up phone call at approximately 60 days after the last dose.
Participants who complete study treatment will be evaluated for surgical exploration for possible R0 or R1 resection. Surgery will occur at least 4 weeks after the last dose (allowing for a wash-out period from treatment) and only after receipt of the recommendation from the central review board with regards to surgical eligibility. Surgery will occur no longer than 8 weeks after the last dose. Participants who undergo surgery will be evaluated for surgical complications for at least an additional 90 days following discharge from surgery.
Participants who are ineligible for surgical exploration (i.e. participants who did not complete study treatment or do not meet any of the protocol defined criteria or had a contraindication to surgery) will continue in the Follow-up period and receive treatment as per standard of care (SOC) for each institution.
All participants will be followed for disease progression (if not previously detected) or recurrence following resection (local progression or metastatic disease). Participants will also be followed for any additional anti-cancer therapy received for their pancreatic cancer. All participants will be followed for survival (until death) or until the last participant to complete treatment reaches 18 months post-treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen GmbH
-
Wien, Austria, 1090
- Medizinische Universität Wien
-
-
-
-
-
Brussels, Belgium, 1070
- CUB Hôpital Erasme
-
-
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre/University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Center
-
-
-
-
-
Chengdu, China
- West China Hospital of Sichuan University
-
Nanjing, China
- Jiangsu Province Hospital
-
Shanghai, China
- Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
-
Shanghai, China
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
-
Beijing
-
Dongcheng, Beijing, China, 100010
- Peking Union Medical College Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Shanghai
-
Jing'an, Shanghai, China, 200040
- Huashan Hospital affiliated with Fudan University
-
-
-
-
-
Besançon Cedex, France, 25030
- CHRU Jean Minjoz
-
Clermont Ferrand, France, 63003
- CHU Estaing
-
Clichy, France, 92118
- Hopital Beaujon
-
Dijon, France, 21079
- Centre Georges-François Leclerc
-
La Tronche, France, 38700
- CHU Grenoble Alpes
-
Lyon, France, 69373
- Centre Léon Bérard
-
Lyon, France, 69437
- Hôpital Edouard Herriot
-
Paris, France, 750013
- Groupe Hospitalier Pitié Salpêtrière
-
Pessac, France, 33604
- Haut-Lévêque
-
Saint Herblain Cedex, France, 44805
- Institut de Cancérologie de l'Ouest Pays de Loire
-
-
-
-
-
Berlin, Germany, 10117
- Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie
-
Dresden, Germany, 01307
- Technische Universität Dresden, Medizinische Klinik und Poliklinik I
-
München, Germany, 81675
- Klinikum Rechts Der Isar Der Technischen Universität München
-
München, Germany, 81377
- Klinikum der Universität München, Medizinische Klinik und Poliklinik III
-
-
-
-
-
Be'er Ya'aqov, Israel, 7030000
- Shamir Medical center Asaf Harofeh
-
Jerusalem, Israel, 9112001
- Hadassah University Hospital Ein Kerem
-
Kfar Saba, Israel, 4428164
- Meir Medical Center
-
Petach Tikva, Israel, 4941492
- Rabin Medical Center
-
-
-
-
-
Meldola, Italy, 47014
- Instituto Scientifico Romagnolog per lo Studio e la Cura dei Tumori
-
Milano, Italy, 20132
- IRCCS Ospedale San Raffaele
-
Milano, Italy, 20141
- Istituto Europeo di Oncologia
-
Milano, Italy, 20162
- Grande Ospedale Metropolitano Niguarda, Oncologia Medica Falck
-
Napoli, Italy, 80131
- AOU Federico II
-
Rozzano, Italy, 20089
- Istituto Clinico Humanitas
-
Verona, Italy, 37134
- CRC di Verona
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
-
Geyonggi-do
-
Seongnam-si, Geyonggi-do, Korea, Republic of, 13620
- Seoul National University Budang Hospital
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- National Cancer Center
-
-
Jeollanam-do
-
Hwasun, Jeollanam-do, Korea, Republic of, 58128
- Chonnam National University Hwasun Hospital
-
-
-
-
-
Barcelona, Spain, 8041
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spain, 08035
- Hospital Universitaro Vall D'Hebron
-
Girona, Spain, 17007
- Institut Catalá d'Oncologia (ICO Girona). Hospital Dr. Josep Trueta
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spain, 28033
- MD Anderson Cancer Center
-
Valencia, Spain, 46010
- Hospital Clinico Universitario de Valencia
-
Zaragoza, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
Pontevedra
-
Vigo, Pontevedra, Spain, 36312
- Álvaro Cunqueiro Hospital
-
-
-
-
-
London, United Kingdom, NW1 2PG
- University College London Hospitals NHS Foundation Trust
-
London, United Kingdom, W2 1NY
- Imperial College Healthcare NHS Trust
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- St. Joseph's Hospital and Medical Cancer Center
-
-
California
-
La Jolla, California, United States, 92037
- UC San Diego Moores Cancer Center
-
Los Angeles, California, United States, 90095
- UCLA
-
Sacramento, California, United States, 95817
- UC Davis Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Illinois
-
Elmhurst, Illinois, United States, 60126
- Elmhurst Memorial Hospital - Nancy W. Knowles Cancer Center
-
Naperville, Illinois, United States, 60540
- Edward Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 48202
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- University of Kansas Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Norton Cancer Institute, Audubon Hospital Campus
-
-
Maine
-
South Portland, Maine, United States, 04106
- Maine Health Cancer Care
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Saint Luke's Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105
- University of Nebraska Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- New Mexico Cancer Care Alliance
-
-
New York
-
New York, New York, United States, 11735
- NYU Langone Health
-
Stony Brook, New York, United States, 11794
- Stony Brook University
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Medical Center
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
West Reading, Pennsylvania, United States, 19611
- Reading Hospital McGlinn Cancer Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Temple, Texas, United States, 76508
- Baylor Scott & White Medical Center
-
The Woodlands, Texas, United States, 77380
- Renovatio Clinic
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Inova Schar Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understand and sign informed consent; be willing to comply with study procedures, including surgery
- Age ≥ 18 years
- Be a male, or non-pregnant and non-lactating female
- Negative serum B-hCG pregnancy test at screening for women of childbearing potential
- Male participants with partners of childbearing potential and female participants of childbearing potential are required to use highly effective contraception methods during the conduct of the study and for 6 months after the last dose of study drug
- Histologically or cytologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC)
- Locally advanced pancreatic cancer considered unresectable according to NCCN Guidelines® Version 2.2018 as determined by central imaging
- Measurable disease as defined by RECIST 1.1 criteria as determined by central imaging
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x upper limit of normal (ULN), alkaline phosphatase <2.5 x ULN, and bilirubin ≤1.5 x ULN or in participants with biliary stenting ≤2.0 x ULN
- Adequate bone marrow function: platelets >100,000 cells/mm3, hemoglobin >9.0 g/dl and absolute neutrophil count (ANC) >1,500 cells/mm3
- Adequate renal function: creatinine < 1.5 x ULN, creatinine clearance ≥ 30 mL/min
- Less than grade 2 pre-existing peripheral neuropathy (per CTCAE)
Exclusion Criteria:
- Prior chemotherapy or radiation for pancreatic cancer
- Previous (within the past 3 years) or concurrent malignancy diagnosis except non-melanoma skin cancer and in situ carcinomas (excluding in situ breast cancer)
- Major surgery within 4 weeks prior to signing informed consent form. Biliary stents are permitted.
- History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
- History of allergy or hypersensitivity to any of the chemotherapy agents being prescribed or their excipients
- Any medical or surgical condition that may place the participant at increased risk while on study
- Any condition potentially decreasing compliance to study procedures
- Exposure to another investigational drug within 28 days of first dosing visit, or 5 half-lives of the investigational drug (whichever is longer)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infections, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Documented history of drug or alcohol abuse within 6 months of signing informed consent
- Any medical condition that, in the opinion of the investigator, may pose a safety risk to a participant in this trial, may confound the assessment of safety and efficacy, or may interfere with study participation
- Participants with a history of interstitial pulmonary disease, hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection
- Participants who have been administered a live vaccine within 4 weeks prior to the first administration of therapy
- Participants who cannot stop chronic medications that inhibit or induce cytochrome P (CYP) 2C8 or CYP3A4
- Participants with poorly controlled comorbid conditions, including; congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), uncontrolled diabetes mellitus (DM) or neurologic disorders (not acutely related to pancreatic cancer) or limited function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
|
Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion. Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Other Names:
|
Placebo Comparator: Arm B
Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
|
Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion. Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: Randomization to death due to any cause or until the last participant to complete treatment reaches 18 months post-treatment
|
Randomization to death due to any cause or until the last participant to complete treatment reaches 18 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Randomization until disease progression or death, whichever occurs first (assessed up to 6 years)
|
Randomization until disease progression or death, whichever occurs first (assessed up to 6 years)
|
|
Event-free survival (EFS)
Time Frame: Randomization until one of the following events, whichever occurs first: resection failure or progression that precludes surgery, local or distant recurrence, death (assessed up to 6 years)
|
Randomization until one of the following events, whichever occurs first: resection failure or progression that precludes surgery, local or distant recurrence, death (assessed up to 6 years)
|
|
Best Overall Objective Response Rate (ORR), as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time Frame: Randomization until centrally-assessed progressive disease (PD), death, or first administration of anti-tumor treatment (other than study medication), whichever occurs first (assessed up to 6 years)
|
Best ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) during treatment period.
|
Randomization until centrally-assessed progressive disease (PD), death, or first administration of anti-tumor treatment (other than study medication), whichever occurs first (assessed up to 6 years)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Paclitaxel
- Fluorouracil
- Leucovorin
- Irinotecan
- Levoleucovorin
- Albumin-Bound Paclitaxel
- Folfirinox
- Gemcitabine
Other Study ID Numbers
- FGCL-3019-087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer Non-resectable
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
Asan Medical CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Cancer Non-resectableKorea, Republic of
-
Rise Biopharmaceuticals, Inc.T-TOP Clinical Research Co., Ltd.RecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectableTaiwan
-
University of OxfordNational Institute for Health Research, United Kingdom; ImunonWithdrawnPancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectableUnited Kingdom
-
University of LouisvilleJames Graham Brown Cancer CenterCompletedPancreatic Cancer Non-resectableUnited States
-
Immunitor LLCUnknownPancreatic Cancer Non-resectableMongolia
-
Shanghai Proton and Heavy Ion CenterRecruitingPancreatic Cancer Non-resectableChina
-
Amsterdam UMC, location VUmcUMC Utrecht; Erasmus Medical Center; Dutch Cancer Society; Viewray Inc.RecruitingPancreatic Cancer Non-resectableNetherlands
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Cancer Non-resectableItaly
Clinical Trials on Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
-
Pancreatic Cancer Action NetworkActive, not recruitingMetastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
University of Colorado, DenverCompletedPancreatic CancerUnited States
-
BioNTech Research & Development, Inc.RecruitingPancreatic CancerUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Nagoya UniversityActive, not recruitingBorderline Resectable Pancreatic Cancer
-
Lyudmyla BerimRecruitingMetastatic Pancreatic CancerUnited States
-
HutchmedNot yet recruiting
-
Onconic Therapeutics Inc.Not yet recruiting
-
Erasme University HospitalJules Bordet Institute; University Hospital St Luc, Brussels; Belgian Group of...RecruitingPancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Pancreatic NeoplasmBelgium
-
Massachusetts General HospitalTerminatedResectable Pancreatic Cancer | Pancreatic Ductal CarcinomaUnited States